Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9802MR)

This product GTTS-WQ9802MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9802MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2182MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ15905MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ995MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ46MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ1233MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ6886MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ13884MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ7438MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW